<DOC>
	<DOC>NCT00246571</DOC>
	<brief_summary>The purpose of this study is to compare progression free survival for SU011248 [sutent (sunitinib malate)] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.</brief_summary>
	<brief_title>Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Recurrent or metastatic breast cancer Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative status Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting Relapse following adjuvant chemotherapy within 6 months of last treatment and/or received one or two chemotherapy regimens for advanced disease More than two chemotherapy regimens for advanced disease Uncontrolled/symptomatic spread of cancer to the brain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>